Efficacy of avian pneumovirus vaccines against an avian pneumovirus/Escherichia coli O2:K1 dual infection in turkeys.
The clinical, pathological and microbiological outcome of a challenge with avian pneumovirus (APV) and Escherichia coli O2:K1 was evaluated in turkeys vaccinated with an attenuated APV vaccine and with or without maternally derived antibodies. Two groups of two-week-old poults, one with and one without maternally derived antibodies against APV, were vaccinated oculonasally with attenuated APV subtype A or B. A third group remained unvaccinated. Eleven weeks later, the turkeys were inoculated intranasally with either virulent APV subtype A, or E. coli O2:K1, or with both agents three days apart. After the dual infection, birds vaccinated with attenuated subtype A or B, and with or without maternally derived antibodies, had lower mean clinical scores than the unvaccinated birds. In the vaccinated birds, virus replication was significantly reduced and no bacteria were isolated, except from the birds vaccinated with attenuated subtype B. In the unvaccinated turkeys, large numbers of E. coli O2:K1 were isolated from the turbinates of the dually infected birds between one-and-a-half and seven days after they were inoculated.
Van de Zande
S
S
Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Nauwynck
H
H
Pensaert
M
M
D000818:Animals; D000914:Antibodies, Viral / Q000302:isolation & purification; D004926:Escherichia coli / Q000276:immunology / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000150:complications* / Q000276:immunology; D022361:Escherichia coli Vaccines / Q000276:immunology*; D018111:Pneumovirus / Q000276:immunology*; D018186:Pneumovirus Infections / Q000276:immunology*; D011201:Poultry Diseases / Q000276:immunology / Q000517:prevention & control*; D014422:Turkeys; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D022361:Escherichia coli Vaccines; D014765:Viral Vaccines